Entities

President of SVB Capital in primary 2020 and 2021 announcements. This is a historical role; current employment is not established by those records.

Historical managing partner of SVB Capital, confirmed in its 2020 conference agenda. Pinegrove Venture Partners identifies him alongside Aaron Gershenberg and Thorben Hett as a leader of its venture fund investment, co-commitment and co-investment program in February 2026.

Venture investment platform formed in 2023 with backing from Brookfield Asset Management and HRTG Partners, formerly Sequoia Heritage. Pinegrove supports the innovation economy through venture fund primaries and co-investments, venture debt and private credit, and technology growth secondaries. Its strategies span artificial intelligence, infrastructure, enterprise software, healthcare, life sciences and defense. Current verified leaders include CEO and managing partner Aaron Gershenberg, managing partners Sulu Mamdani and Thorben Hett, and partner Dave Mullen. Pinegrove acquired the distinct SVB Capital operating platform in September 2024, which was rebranded Pinegrove Ventures. Its Strategic Investors Fund XII closed at $1.5 billion on September 10, 2026 across Early and Scale strategies; the platform-wide $15 billion-plus AUM is not the size of that fund. Ramp explicitly named Pinegrove Venture Partners in its June 2026 Series F.

Historical venture capital and private credit investment platform founded in 1999 within SVB Financial Group. SVB Capital managed venture fund-of-funds, direct company investments, co-investments and venture debt strategies for institutional limited partners, with exposure to technology, AI, deep technology and life sciences. Its verified historical team includes co-founder Aaron Gershenberg, Sulu Mamdani, John China, Efrat Turgeman, Carolyn Mazonson and former life-sciences investment lead Jennifer Friel Goldstein. Komodo Health named SVB Capital in its March 2021 Series E. The business was acquired through a Pinegrove affiliate on September 26, 2024 and rebranded Pinegrove Ventures; its historical records remain separate from Silicon Valley Bank, the operating bank, and the Pinegrove umbrella formed in 2023. Historical SVB Capital logo and team roles are expressly identified as such. AppliedVR named SVB Ventures in 2021; the exact legal or manager alias has not been independently resolved and is not assigned to this profile.

Pierre Mozer is Chief Medical Officer and co-founder of UroMems and a board observer. He is a practicing urologist and Sorbonne University professor whose research spans smart systems, robotics and clinical urology. He completed an information technology doctorate at Joseph-Fourier University and postdoctoral work at Johns Hopkins.

Rinda Sama is a UroMems director with medical-device operations and quality experience. He was formerly Chief Operating Officer at Axonics and previously led operations and quality at Vessix Vascular. He holds a biomedical engineering master’s from USC and an MBA from the University of California, Irvine.

Johannes Fischer is a UroMems director and a life sciences investor at Wellington Partners. Wellington’s current directory lists him as Managing Partner; he joined in 2020 and previously worked in life sciences strategy consulting at L.E.K. He holds biochemistry, biotechnology and medical qualifications from Technical University Munich.

Jeremy Durack is a UroMems director and Partner and Senior Vice President of Medical Affairs at Ajax Health. He is an interventional radiologist and former Vice-Chair of Radiology at Memorial Sloan Kettering Cancer Center. He trained in psychology and neuroscience at Duke, medicine at Stanford, and radiology and informatics at UCSF.

Jérôme Feraud is a UroMems director and Head of the Health Division at Crédit Mutuel Innovation. His prior investing experience includes ACG Management and GO Capital. He holds a master’s in immunology and an executive MBA from IAE Aix.

Philippe Boucheron is a UroMems director and Deputy Chief of Life Sciences Investment at Bpifrance. He co-founded Bioam Funds in 2000, which subsequently became part of Bpifrance through mergers. His background includes BioCapital and ING Barings; he trained in biochemical engineering and holds an INSEAD MBA.

David Beylik is a UroMems director and Partner at Ajax Health. His background includes operating responsibilities at Maverix Medical, corporate law at Latham & Watkins and a clerkship for U.S. Supreme Court Chief Justice John Roberts. He studied at Harvard Law School and the University of Southern California.

Stéphane Lavallée is a co-founder and board member of UroMems. He is a medical robotics entrepreneur whose work includes image-guided surgical robotics, Praxim, eCential Robotics, Orthotaxy and the BizMedTech/MinMaxMedical accelerator. His earlier surgical robot work with Professors Benabid and Cinquin was applied in neurosurgery.

Dan Rose chairs UroMems and is CEO of Endovascular Engineering. He previously led LimFlow through its acquisition by Inari Medical and held leadership roles at Direct Flow Medical, Sequana Medical and Medtronic. He holds degrees from the University of Virginia and an MBA from its Darden School.

Hamid Lamraoui is CEO and co-founder of UroMems and a member of its board. A biomedical engineer, he has led the development of its implantable mechatronics platform since inception. He earned his engineering degree at Aix-Marseille University and a biomedical engineering doctorate at Grenoble University.

UroMems is a medical-device company founded in 2011 by biomedical engineer Hamid Lamraoui, urologist Pierre Mozer and medical robotics entrepreneur Stéphane Lavallée. Based in the Grenoble area of France with operations in Minneapolis, it develops implantable mechatronic systems for stress urinary incontinence. Its UroActive electronic artificial urinary sphincter combines embedded software, sensing, microtechnology and automated control to adapt urethral pressure to a patient’s activity. This is deep technology for urological function rather than a brain-computer interface. The system remains investigational: FDA investigational-device exemption and French ANSM clearance enabled the SOPHIA2 pivotal trial in 2025; these were trial permissions, not marketing authorizations. The company’s May 2026 announcement says the trial is ongoing across U.S. and French sites and the device is not available for sale in the U.S. or EU. The published leadership comprises three co-founders, nine board members, four board observers and three clinical advisers, with overlap among these groups. Documented financing includes a €12 million Series A in 2016, a €16 million equity-and-debt first Series B tranche in 2020 plus an additional €7 million in 2021, a €44 million Series C in 2024, and a $60 million strategic financing exclusively from Ajax Health Fund I in May 2026. HIL-INVENT is a verified investor in the 2020, 2021 and 2024 financings; it is separate from the EVER Pharma operating group.

Co-founder, CEO and board chairman of Fin, the AI customer-agent company founded as Intercom in2011 and renamed in2026. He earlier founded software design company Contrast and developer toolkit Exceptional. He is a personally named investor in Paradigm AI’s USD2 million pre-seed financing; no Fin or Intercom corporate check is implied.

Arnie Fishman is a co-founder of AppliedVR. Fellow co-founder David Sackman identifies Fishman, Matthew Stoudt and Josh Sackman as his founding partners in the immersive therapeutics company.

David Sackman is a co-founder and founding chairman of AppliedVR. After leading LRW and Material, he became CEO of Bovitz in 2025. AppliedVR's own founding narrative identifies him alongside Matthew Stoudt and Josh Sackman.

Emily Judge is Vice President of Access and Partnerships at AppliedVR, developing partnerships for its market access and commercial strategies.

Clinical-stage biotechnology company developing oral small-molecule treatments for autoimmune and chronic inflammatory diseases. Formerly Onco3R Therapeutics, it uses salt-inducible kinase biology and an AI-augmented drug-design platform to optimize medicines. Its lead candidate COL-5671 is a selective, once-daily oral SIK3 inhibitor in Phase 1 development, with planned Phase 2 studies in psoriasis and ulcerative colitis. It also has discovery programs in immunology and metabolic disease.

Develops AI-powered blood tests to monitor chronic diseases and organ health. Its Whole-Body Atlas combines characterized human tissue samples with DNA methylation and protein biomarkers to train Whole-Body Intelligence models that trace disease signals in blood. Initial applications include monitoring liver disease progression, cirrhosis and hepatocellular carcinoma. The company is developing and clinically validating these tests for physicians and other healthcare partners.

NRG Therapeutics is a UK clinical-stage neuroscience company developing oral, brain-penetrant medicines for ALS and Parkinson’s disease. Its small molecules target the mitochondrial regulator NLRX1 to inhibit opening of the mitochondrial permeability transition pore, aiming to preserve neuronal energy production and reduce neuroinflammation and neuron loss. Lead candidate NRG5051 is being evaluated in a Phase 1 trial in healthy adults and people with ALS or Parkinson’s; Phase 2 proof-of-concept development in ALS is planned. The medicines are investigational.

SciThera is a San Diego biotechnology company developing antibody drug conjugates for cancer and autoimmune diseases. Its work builds on antibody engineering expertise: in 2025, it licensed antibody-library assets from Inhibrx and took over an agreement with NorthStar Medical Technologies to develop cancer radiopharmaceuticals. Founded by former Inhibrx chief scientific officer Brendan Eckelman, the company is backed by Luma Group, Alta Partners and Venrock. Its therapeutic targets and detailed pipeline remain undisclosed publicly.

Treventis develops small-molecule medicines that prevent disease-causing proteins from misfolding and forming toxic aggregates. Its patented Common Conformational Morphology discovery platform combines computational models of misfolded proteins with laboratory and animal testing to identify druggable sites. A tau oligomer inhibitor program for Alzheimer’s disease and tauopathies is partnered with Takeda; separate discovery programs target amyloid-beta aggregation, TDP protein aggregation in ALS and frontotemporal dementia, and mutant p53 aggregation in cancer.

Vaccine Company develops next-generation vaccines using In Vivo Nanoparticle technologies that combine mRNA and virus-like-particle approaches to display multiple antigens and seek durable immune responses while reducing manufacturing complexity. Its lead five-antigen Epstein-Barr virus vaccine was ready for Phase 1 development when the company announced its sale to Eli Lilly in May 2026; preventing EBV could also reduce associated long-term neurological and oncological disease. Founded in 2022 by ARCH Venture Partners, with Luma Group joining as a co-founding investor, the company is now included in Lilly’s subsidiary portfolio. It also received an ARPA-H research award for flavivirus vaccines.

Aakriti Singh is a research associate at Character Biosciences. This identity is distinct from the TDK Ventures investor of the same name.

Vaccine Company protein sciences director, according to the Peter Kim Lab alumni directory; previously a Stanford postdoctoral scholar.

Adria Frazier is published by Character Biosciences as Senior Research Associate.

Former Head of Product and Program Management at GRAIL, where she led strategy for a multi-cancer early detection blood test, after leadership roles at Natera, Progyny, and Sienna Biopharmaceuticals.

Chief of Hepatology and Willis C. Maddrey, M.D. Distinguished Chair in Liver Disease at UT Southwestern Medical Center with 400+ publications over his 25+ year clinical career.

Andrea Neeranjan is published by Character Biosciences as Associate Director, Clinical Research.

Brendan Curran is published by Character Biosciences as Engineering Lead.

Founder and chief executive of SciThera; previously co-founded Inhibrx and served as its chief scientific officer.

Charlotte Kremers is Principal at M Ventures. Biotechnology principal who entered the programme as a fellow in2022. Holds Utrecht biology/physiology/neuroscience BSc and UCL neuroscience MSc/PhD, with doctoral research into juvenile ALS mechanisms. Current Principal directory title supersedes older Associate narrative; existing NRG board affiliation preserved.

Cheng Zhang is published by Character Biosciences as CEO, Co-Founder.

Founding Scientist and Senior Site Director at Counsyl, where he led the automation, delivery, and scaling of advanced blood tests for prenatal screening and hereditary cancer screening.

Claudio Nessi is named on Anaconda Biomed’s current public board of directors. The issuer identifies the affiliation as OMEGAFUNDS-NeoMed. This confirms the board relationship without establishing a personal investment. Claudio Nessi joined Omega as a Managing Director in 2016 and serves on its investment committee. He previously became a partner at NeoMed after joining in 2001 and worked at Genevest. His scientific career included Max Planck and University of Connecticut research; he holds a Pavia doctorate and an Erasmus MBA.

Daniel Elgort is published by Character Biosciences as Chief Data and Analytics Officer.

Danielle Clark is published by Character Biosciences as Scientist.

David Buchholz is published by Character Biosciences as Senior Scientist.

Dinah Chen is published by Character Biosciences as Medical Director and Clinical Innovation Lead.

Dylan Henry is published by Character Biosciences as Contracts Manager.

Erik Karrer is published by Character Biosciences as SVP, Drug Discovery.

Fabrice A.

Francesco Draetta became an Omega Managing Director and investment-committee member in 2023. He first worked at Omega from 2008 to 2012 and returned in 2016 after roles at Brookside and Commonfund. His qualifications include CFA, CAIA and FRM credentials.

A seasoned cancer biologist and drug discovery leader, he brings over 20 years of experience in oncology research, with a focus on precision medicine and translational science.

Geraldine Taveras is published by Character Biosciences as Senior Clinical Research Coordinator.

Gert De Beckker is a biopharmaceutical executive with more than 25 years of experience in global regulatory affairs and drug development.

Guy Peeters has over 20 years of experience in finance leadership within the pharmaceutical and biotech sectors.

Hakan Goker is a TRIMTECH non-executive director and M Ventures biotechnology managing director. He previously invested at Aescap Venture and Atlas Venture. His scientific training includes oncology research at the Institute of Cancer Research and postdoctoral work at the Royal Marsden; he is based in Amsterdam.

Computational biology and AI scientist; CTO at Kimia Therapeutics, formerly at Recursion and Freenome.

Isabel Varela is published by Character Biosciences as Operations Analyst.

Stanford biomedical data science associate professor researching reliable AI for health and disease, formerly at Microsoft Research.

Jasmin Bharadiya is published by Character Biosciences as Senior Data Engineer.

Jessamyn Wead is published by Character Biosciences as Head of People.

First chief executive and a former board director of Vaccine Company; previously led Merck Global Vaccines.

John-Paul Gallivan, currently serves as our Head of Development at Coultreon Biopharma and has over 15 years of experience in the biotech and pharmaceutical industry.

Jonathan Savidge, registered as Jonathan Rex Savidge, is an active statutory director of Acionna Therapeutics Ltd, appointed April24,2025. His Companies House appointment history also identifies NRG Therapeutics; board affiliations do not imply company employment.

With over 25 years of experience in antibody discovery and development, he has played a key role in advancing therapeutic candidates in oncology, immunology, and infectious diseases.

Josh Buddle is published by Character Biosciences as Head of Clinical Network and Longitudinal Research.

Julia Myers is published by Character Biosciences as Senior Research Associate.

Vaccine Company chief medical officer in its 2024 filing and principal investigator for its ARPA-H A-FAVE flavivirus vaccine project. Previously worked at the NIH Vaccine Research Center.

Kaila Smilen is published by Character Biosciences as VP, Corporate Development.

Katherine Jackman is senior investment manager at Brandon Capital. She joined in2016 after experimental-stroke research at Weill Cornell and the Florey Institute. Her research investigated progranulin deficiency, cerebral vessels and stroke susceptibility, connecting neurodegeneration research with life-sciences investing. Existing NRG issuer affiliation remains intact. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Genomic diagnostics researcher and R&D executive at Fellow; formerly held product development roles at CareDx and Exact Sciences.

Scientific executive at Eigen Bio with former discovery research roles at Veracyte and Guardant Health; specializes in AI and genomics.

Laura Macri is published by Character Biosciences as Associate Director, Study Operations.

Lawrence M.

Lieve is a senior nonclinical safety leader with more than 30 years of experience across global pharma and biotech.

Maha Katabi is a General Partner of Sofinnova Investments.

Marcel van der Brug is published by Character Biosciences as Scientific Advisor, Co-Founder.

Maria Avrutsky is published by Character Biosciences as Senior Scientist.

A seasoned legal executive with over 15 years of experience in the biotech and pharmaceutical industries, she brings deep expertise in R&D collaborations, business development, and strategic transactions.

Max Klement is a Partner at Novo Holdings Venture Investments, based in London. Max joined Venture Investments in 2022 and is based in the London office. Previously, Max was a Principal at BGV, a life science venture capital firm specialized in early stage companies, where he focused on investments in Europe, the United States, and led multiple company creation initiatives. Max served on the Board of Directors of Complement Therapeutics and was an observer on the Board of Directors of Dualyx, Link Immunotherapeutics, and VarmX. Prior to BGV, he worked in various operational roles at Eden Biologics, a biologics CDMO, and at Hummingbird Bioscience, a company leveraging systems biology for antibody discovery and development. Max studied protein engineering for applications in regenerative medicine as an A*STAR fellow. He holds a PhD in Chemical and Biomolecular Engineering from the National University of Singapore, a BS in Biochemical Engineering from the University of California Irvine, and a Master’s in Business Administration from INSEAD.

May Chen is published by Character Biosciences as Director, Drug Discovery.

Mayssa Attar serves on Character Biosciences’ board; the company lists their affiliation as Bausch + Lomb.

Nate Massari brings more than 25 years of experience across business development, strategy, and commercialization in the biopharmaceutical industry.

Previously Head of R&D at Natera and Head of R&D at GRAIL, where he led the development of advanced blood tests for oncology, prenatal screening, and hereditary cancer screening.

Nathaniel Mooi is published by Character Biosciences as Senior Research Associate.

Vaccine Company protein and virus sciences director, according to the Peter Kim Lab alumni directory; previously trained as a graduate student in the laboratory.

Peter DiLaura serves on Character Biosciences’ board; the company lists their affiliation as Independent.

UCSF clinical informatics assistant professor researching AI, digital diagnostics and health monitoring.

Coultreon Biopharma co-founder, CEO, chief scientific officer and board member. Drug discovery executive with former leadership roles at Galapagos, Aligos Therapeutics and Janssen.

With over 25 years of experience in the pharmaceutical industry, he brings deep expertise at the intersection of data science, bioengineering, and technology-driven drug discovery.

Dr.

Venrock healthcare partner and board director of SciThera, with prior biotechnology business development and commercial experience at Clovis Oncology.

Reut Shema serves on Character Biosciences’ board; the company lists their affiliation as aMoon. Reut Shema is published by aMoon as Partner. Scientist whose research experience includes Harvard, MIT and the Weizmann Institute; joined in2018 and also works on the Edge public-equity strategy.

Formerly in Business Development at Genentech, where he led partnership efforts in AI-enabled testing, trials, and therapeutics. Expert in AI, data engineering, and patient monitoring.

Robert Kim is published by Character Biosciences as Chief Medical Officer.

Rogier is a general Partner at Forbion.

Stanford professor and biomedical informatics and healthcare AI researcher; co-founder of Personalis. Russ Altman, MD, PhD, is a Stanford professor of bioengineering, genetics, medicine and biomedical data science and a senior fellow at the Stanford Institute for Human-Centered Artificial Intelligence. Weave Bio appointed him to its inaugural Strategic Advisory Board inMarch2026. His advisory role supports responsible AI in regulatory science.

Ryan Campbell is published by Character Biosciences as Senior Research Associate.

A highly accomplished medicinal chemist, she brings over 20 years of experience in drug discovery and development in oncology and virology.

Saoussen Ben Halima joined Omega in Geneva in 2022 and is a Principal. She previously worked at Roche and Medicxi. Her scientific training includes a neuroscience doctorate at ETH Zurich and Alzheimer disease research at the University of Zurich, with earlier studies at ENS and McGill.

Leland T. Edwards Professor in the School of Engineering at Stanford University with 300+ publications and 70+ issued or pending patents over his 30+ year academic career.

Named chief financial officer in Vaccine Company’s California statement of information filed June 14, 2024.

Data science, statistics and bioinformatics specialist, formerly senior vice president of R&D at Natera.

Sumra Farooq is published by Character Biosciences as Clinical Data Manager.

Led Vaccine Company before its acquisition by Eli Lilly; previously held global vaccine and emerging-markets leadership roles at Pfizer.

Tejasveeta Nadkarni is published by Character Biosciences as Associate Scientist.

Tom Govaerts is a senior CMC Leader / Senior Director and brings over 25 years of experience in the pharmaceutical industry.

Vivek Garipalli serves on Character Biosciences’ board; the company lists their affiliation as Clover Health. Vivek Garipalli is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Founder & Board Member, Clover Health; that title is context, not an executive position at Thyme Care.

Wendy Lin is published by Character Biosciences as Associate Director, Clinical Operations and Clinical Science.

Genomic diagnostics scientist and chief scientific officer at Droplet Biosciences; previously held scientific leadership roles at Glympse Bio, Novartis and the Broad Institute.

Yunju Yang is published by Character Biosciences as Human Genetics Lead.

Zachary Katz is published by Character Biosciences as Director, Strategic Initiatives & Alliance Management.

Keith Brady, JD, is Vice President of Sales at AppliedVR, leading sales growth and revenue expansion.

Ken Drazan is ArsenalBio’s co-founder, chairman and chief executive officer, as confirmed in its August 2026 strategy announcement.

Genomics and bioengineering researcher at Altos Labs studying cellular health using genome technologies, epigenomics and single-cell sequencing; previously chaired bioengineering at the University of California, San Diego.

Apollo Health Ventures current own career biography: Nils co-founded Apollo Health Ventures in 2017 and is one of the most successful German investors and a serial entrepreneur with six exits since 2009 He utilizes his deal-making skills, impeccable business sense, and his expertise in growing early-stage startups to support the Apollo portfolio Nils and the founding team have successfully raised two fund generations, hired the senior team, and led investments as well as follow-on investments in Apollo's portfolio companies Nils studied business in Hamburg and at UC Santa Barbara (UCSB) in California, and he completed the EO Entrepreneurial Masters Program at MIT Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Myles Guanzon is Vice President of Engineering at AppliedVR, a product development executive with more than 15 years of experience in digital health.

Todd Maddox, PhD, is Vice President of Research and Development at AppliedVR. He applies brain science, data and psychology to immersive therapeutics. AppliedVR's official NIH SBIR awards identify him as principal investigator William T. Maddox.

Beth Darnall, PhD, is Chief Science Advisor at AppliedVR. Her work centers on pain treatment methodologies that empower patients.

Stevie Cogan is Head of People at AppliedVR, responsible for company culture, talent and people development.

Oliver Koechli is Chief Operating Officer of AppliedVR, overseeing day-to-day operations and administrative efficiency.

Los Angeles-based immersive therapeutics company developing virtual reality products for pain management. Its prescription RelieVRx device, formerly EaseVRx, delivers an eight-week program incorporating cognitive behavioral skills, breathing and mindfulness for adults with chronic low back pain. The FDA granted EaseVRx De Novo marketing authorization in November 2021; this does not establish authorization for other conditions. The company's SustainVR product is a general wellness device offered within the US Department of Veterans Affairs. Founded in 2015, AppliedVR combines behavioral science, neuroscience and medical-device engineering, with research programs supported by NIH SBIR awards. It announced a USD29 million Series A in March 2021 and a USD36 million Series B in November 2021. Research partnerships, reimbursement and cumulative financing totals are distinct from individual funding rounds.

Josh Sackman is co-founder and President of AppliedVR. His work at the intersection of healthcare and technology and his experience as a pediatric patient informed the company's focus on accessible pain management.

Matthew Stoudt is co-founder and CEO of AppliedVR, which he founded in 2015. His earlier entrepreneurial work was in digital media; he now leads the company's immersive therapeutics business.

Co-founder and CEO of LangChain, developing infrastructure for AI agents and applications. He is a personally named investor in Paradigm AI’s USD2 million pre-seed financing, according to its August2025 launch release; this is distinct from a LangChain corporate investment.

Jürgen Blumberg is Head of Business Development at NaroIQ, according to his announcement republished by the company. He previously joined its expert board before expanding his contribution into a full-time business development role.

Leona Turner is listed by NaroIQ as Chief of Staff. NaroIQ develops digital infrastructure for ETFs and investment funds.

Nils Krauthausen co-founded NaroIQ with Chris Puellen in 2022. The company builds digital infrastructure for launching and administering ETFs and investment funds. Its current homepage does not publish a present executive title for Krauthausen.

Seda Tunç Soylu is listed by NaroIQ as Head Of Fixed Income. NaroIQ develops digital infrastructure for ETFs and investment funds.

Tim Entenmann is listed by NaroIQ as Product. NaroIQ develops digital infrastructure for ETFs and investment funds.

Christian Meyer-Vahrenhorst is listed by NaroIQ as Managing Director. NaroIQ develops digital infrastructure for ETFs and investment funds.

Hendrik Mechlinski is listed by NaroIQ as Managing Director. NaroIQ develops digital infrastructure for ETFs and investment funds.

Chris Puellen is listed by NaroIQ as CEO and Co-Founder. NaroIQ develops digital infrastructure for ETFs and investment funds.

Nico Hamann is listed by NaroIQ as Head Of Indexing. NaroIQ develops digital infrastructure for ETFs and investment funds.

Moritz Schierholz is listed by NaroIQ as Head Of Portfolio Management. NaroIQ develops digital infrastructure for ETFs and investment funds.

Andy Bair is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

David Dill is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Donna Wells is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Karl Wagner is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Kip Quackenbush is listed by Sway Capital as Advisor, Sway Studios. The published role is advisory; no personal cash investment is inferred.

Marwan Fawaz is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Sam Howard is listed by Sway Capital as Principal, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Yasmin Moaven is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Najwa Nasif is listed by Sway Capital as Manager of People, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Jessica Gonzalez is listed by Sway Capital as Accountant, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Bret Awbrey is listed by Sway Capital as VP, Finance, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

John McGuinness is listed by Sway Capital as Partner, GC & CCO, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Thalia Gietzen is listed by Sway Capital as CFO, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Megan Ellertson is listed by Sway Capital as Office Manager, Executive Administration, Sway Capital.

Kathleen Hamil is listed by Sway Capital as Manager, Fund Administration, Sway Capital.

Louay Karana is listed by Sway Capital as Sr. Accounting Manager, Sway Capital.

Nicholas Ferrall is listed by Sway Capital as Strategic Advisor, Sway Media. The published role is advisory; no personal cash investment is inferred.

Tobin Armbrust is listed by Sway Capital as Producer, Sway Media.

Nick Johnson is listed by Sway Capital as Associate, Sway Capital.

Brennan Reif is listed by Sway Capital as Principal, Sway Capital.

Terrence Battle is listed by Sway Capital as Sr. Principal, Sway Studios.

Vincent Monteparte is listed by Sway Capital as Venture Partner, Sway Ventures.

Domini Kelly is listed by Sway Capital as Partner, Fund Administration, Sway Capital.

Lani ONeill is listed by Sway Capital as Partner, Sway Capital.

Patrick ONeill is listed by Sway Capital as Partner, CMO, Sway Capital.

Albert Vazquez-Agusti is listed by Sway Capital as Partner, Sway Ventures.

Giovanni Agostinelli is listed by Sway Capital as Partner, Sway Capital.

Shelly Kapoor Collins is listed by Sway Capital as Managing Director, Sway Impact.

Andrew Trapani is listed by Sway Capital as Managing Director, Sway Media.

Marlon Evans is listed by Sway Capital as Managing Director, Sway Impact & Sway Studios.

Najib Khouri-Haddad is listed by Sway Capital as Managing Director, Sway Ventures.

Ken Denman is listed by Sway Capital as Managing Director, Sway Ventures.

Bill Malloy is listed by Sway Capital as Co-Founder, Sway Capital.

Greg White is listed by Sway Capital as President & COO, Sway Capital.

Brian Nugent is listed by Sway Capital as Co-Founder, Sway Capital.

Venture capital platform of Sway Capital, investing in early-stage technology companies from seed through growth. Its investments span AI software, healthcare technology, supply-chain technology, fintech, real estate technology and retail technology. Published venture portfolio examples include AppliedVR, Affinity, Airkit, Addepar, Yva AI and Zanbato; AppliedVR develops prescription virtual reality for chronic pain. Current Sway Ventures team members include managing directors Ken Denman and Najib Khouri-Haddad, partner Albert Vazquez-Agusti, venture partner Vincent Monteparte and six advisers. The current platform reports 67 portfolio companies and 29 exits. Sway Ventures Management LLC is the regulated adviser (CRD170302); reported private-fund asset values are not fund-closing amounts. The former swayvc.com website redirects to Sway Capital, whose multi-strategy activities and other teams are recorded separately.

Jonny P. leads defence and partnerships at RevEng.AI. He previously served as a Royal Engineer officer and worked as Head of Commercial at Egregious. He supports the company’s government and enterprise relationships. He uses an abbreviated surname in the company’s public welcome announcement.

Robert Marsal is Head of Engineering at RevEng.AI, building its AI and binary-analysis platform. His engineering leadership role is confirmed by the company and his own GitHub profile.

Henry Charlesworth leads machine learning research at RevEng.AI. He previously worked at Rowden Technologies and undertook postdoctoral deep reinforcement-learning research in Warwick’s WMG data science group.

James Patrick-Evans is founder and CEO of RevEng.AI, building AI models for reverse engineering and binary software analysis. He leads the company’s work on software supply-chain verification.

London cybersecurity company founded by James Patrick-Evans in 2023, developing specialised AI for reverse engineering, binary analysis and software supply-chain verification. RevEng.AI analyses compiled executables, firmware and third-party software without source-code access to help security teams identify hidden functionality, malicious components, vulnerabilities and suspicious changes between releases. Its original BinNet approach has expanded into the Mega Bite model suite: WilBERT learns function similarity across binaries and architectures, while Ventris reconstructs readable code from compiled software. The product combines malware analysis, code search, decompilation and security workflows, with integrations for tools such as Ghidra and IDA and developer SDKs. Published benchmark results are company evaluations, with stated limits on semantic equivalence and architecture coverage. Known leadership includes Founder and CEO James Patrick-Evans, Lead ML Research Scientist Henry Charlesworth, Head of Engineering Robert Marsal and Head of Defence & Partnerships Jonny P. The company announced a $4.15 million seed round in June 2025 and a $15 million Series A in May 2026, following an earlier pre-seed of undisclosed amount and date. NCSC for Startups and Intel Ignite participation are accelerator support, distinct from equity funding. Its current website identifies UK company number 14818671; secondary records for an older dissolved entity should not be treated as its current operating status.

Jay Fuller co-founded Statespace with Wayne Mackey in2017. A neuroscientist, he helped build AI-powered training tools for perception, decision-making and motor coordination. NYU and Lux Capital identify him as co-founder. His research laboratory’s current alumni page lists him at Equinox; his Statespace founder relationship is historical and does not imply a current executive job.

Member of Paradigm AI’s founding team. She announced joining the company in a public professional post accompanying its 2026 workflows launch.

Member of Paradigm AI’s founding team, identified in its August2025 company launch announcement. Specific executive title and current continuation were not independently disclosed.

Roberto Sanabria is a director of State Space Labs, Inc., confirmed in its April2026 SEC filing. He is a founding partner at Expa, whose own current team page identifies him and publishes his portrait. This investor and company director is distinct from similarly named actors and other professionals.

Wayne Mackey is co-founder and CEO of Statespace, the developer of Aimlabs. He trained in neuroscience at New York University and applies cognitive science and machine learning to gaming performance. State Space Labs’ April2026 SEC filing confirms him as CEO and director.

Founder and CEO of Paradigm AI, developing agentic spreadsheets and structured-data research workflows. She studied computer science and entrepreneurship at the University of Pennsylvania and participated in Y Combinator Winter2024.

Member of Paradigm AI’s founding team, identified in its August2025 company launch announcement. Specific executive title and current continuation were not independently disclosed.

San Francisco AI software company founded by Anna Monaco, building a spreadsheet interface for agentic research and structured-data workflows. Paradigm runs parallel AI agents to research accounts, enrich and analyze data, monitor signals and update CRM systems with source-backed results. Its published 2025 founding team included Anna Monaco, Michael Alfano and June Lee; Monaco remains the founder and CEO in Y Combinator’s current profile. It announced USD5 million seed financing led by General Catalyst in August2025 and a separately disclosed USD2 million pre-seed from Y Combinator and angel investors, totaling USD7 million. This is separate from Paradigm Health’s clinical research platform and from crypto companies with the same name.

Advisory board member of Paradigm Health and former US Secretary of Veterans Affairs. David J. Shulkin is published by aMoon as External Adviser. Former US Secretary of Veterans Affairs and VA undersecretary for health, with healthcare leadership and public-service experience. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Retired US Army general and board member of Paradigm Health. He previously served as chief operating officer for Operation Warp Speed.

Board member of Paradigm Health and former CEO of Jefferson Health, bringing healthcare leadership experience to clinical research access.

Chief Technology Officer of Paradigm Health, leading its clinical research platform development. He previously served as CTO of Orchard and vice president of engineering at Flatiron Health, and studied computer science at Georgetown. Elijah Meerson is published in the Irregular Expressions directory as Advisor / Limited partner (published directory affiliation). The directory summarizes this professional background: CTO @ Paradigm , CTO @ Orchard , VP Engineering @ Flatiron Health , Engineering Manager @ AppNexus. Outside-employer job titles are reproduced as directory background and are not independently asserted as current appointments.

Chief Operating Officer of Paradigm Health, overseeing sponsor, provider and internal operations. She previously served as COO of Vori Health and held leadership roles at Honor, Lyric and McKesson Technology. She studied at Harvard and Wharton. Distinct from the Michelle Lee associated with Lux Capital, Medra, AI Fund and SignalFire.

Chief Financial Officer of Paradigm Health, responsible for financial strategy and operations. His previous roles included finance leadership at PRA Health Sciences, chief finance and operations officer at Science37 and CEO of Clinverse.

Chief Strategy and Growth Officer at Paradigm Health, working on wider access to clinical research. He previously co-founded Synapticure and chaired its advisory board. His Stanford biological sciences training specialized in neuroscience. Jonathan Hirsch — Synapticure publishes the following professional biography and affiliation: Jonathan Hirsch is a company founder, investor, and advisor at the intersection of healthcare, life sciences, and data. Jonathan founded Syapse in 2008, and during more than a decade of building the company, Jonathan defined and implemented a vision for transforming cancer care through precision medicine and real world evidence. Jonathan serves on the Advisory Boards of companies including Freenome, VizAI, and PaigeAI, and has helped shape the regulatory use of real world evidence through creating and serving as Principal Investigator for a Research Collaboration with the FDA. Jonathan has catalyzed national cancer data sharing networks, including serving on the White House Cancer Moonshot Data Sharing Working Group. As both an active investor and partner in venture funds, including the Kleiner Perkins seed fund and Rebel Fund, Jonathan has incubated and invested in dozens of companies at the intersection of healthcare and technology. The affiliation is scientific/strategic advice; outside employer and university titles remain external.

Founder and CEO of Paradigm Health, developing AI-enabled clinical research infrastructure. He previously served as ICON chief innovation officer and PRA Health Sciences chief scientific officer, with three decades of clinical research experience.

Alex Shalek serves on Relation’s Scientific Advisory Board. Relation identifies him as the J. W. Kieckhefer Professor in MIT’s Department of Chemistry, contributing expertise relevant to single-cell biology.

Benjamin Swerner is co-founder and Chief Operating Officer of Relation, overseeing operations at the AI-enabled drug-discovery company. The company and its transaction counsel identify him as a founder; its current directory also lists him in the board and observers group.

Caroline Uhler serves on Relation’s Scientific Advisory Board. The company identifies her as an MIT professor and co-director of the Eric and Wendy Schmidt Center at the Broad Institute.

Charles Roberts is co-founder and Chair of Relation, according to its current directory and 2024 company financing announcement. The company links his professional profile as Charles Powell Roberts; conflicting middle names in other issuer and legal records have not been used to infer a legal-directorship history.

Dave Powell is President of Drug Discovery at Relation, leading the drug-discovery work of its technology-enabled biopharmaceutical business. His original portrait and exact current title appear in the company’s executive directory.

David Roblin is Chief Executive Officer of Relation, leading AI-assisted drug discovery and development. He previously led European R&D at Pfizer and held senior scientific-translation and executive roles at the Francis Crick Institute. The company appointed him CEO in June 2022.

Jacob Corn serves on Relation’s Scientific Advisory Board. The company identifies him as Professor of Genome Biology at ETH Zurich and co-founder of Spotlight Therapeutics.

Jake Taylor-King is Chief Innovation Officer and a co-founder of Relation. He is part of the company’s leadership and its published board and observers group, combining computational innovation with experimental drug discovery.

Jim Mellon is listed in Relation’s board and observers directory, which identifies his external affiliation as deputy-chair of Juvenescence. His inclusion does not establish a personal equity purchase in a specified Relation round.

Joanna Soroka is listed in Relation’s board and observers group and works on healthcare and techbio investing at Hitachi Ventures. Hitachi’s own current profile calls her Investment Partner, while Relation’s directory retains Principal. Her background includes biochemistry, genetics and oncology research and healthcare strategy.

John Wesley is Investment Director at NVentures and is listed in Relation’s current board and observers group. NVentures is NVIDIA’s venture capital arm; his board-related affiliation does not imply a separate personal investment. John Wesley is publicly identified with NVentures as Senior Investment Director. His published biography describes investment and advisory work at Morgan Stanley, Bain, H.I.G. and Pequot, and operating finance roles at Omniox and as Dren Bio co-founder and CFO.

John Whittaker serves on Relation’s Scientific Advisory Board. Relation identifies him as Director of the MRC Biostatistics Unit and Professor of Biostatistics at the University of Cambridge.

Jonathan Milner founded Abcam and is an angel investor in Relation Therapeutics. Relation explicitly names him in its June2022 seed and March2024 additional seed financings. Jonathan Milner is listed by Cambridge Innovation Capital as advisory panel member. Founded Abcam and trained in molecular genetics; his published background includes support for early life-science ventures. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets. Jonathan Milner co-founded Abcam and the Milner Therapeutics Institute. Start Codon identifies him as a founding backer, while Companies House records his historical Ltd director appointment15April2019–3December2021. Its current owner identifies Meltwind as his diligence/portfolio-management team; no undisclosed personal ticket or current Start Codon director appointment is inferred. Jonathan Milner is publicly named by Cambridge Angels in its selected individual-member directory. Membership is an angel-network affiliation: individual investment choices are independent, and membership alone does not prove personal investment in any portfolio company.

Lindsay Edwards is Chief Technology Officer at Relation. Before joining in 2022, he led artificial-intelligence work in respiratory and immunology at AstraZeneca and earlier led AI and data-science groups at GSK.

Marc Wein serves on Relation’s Scientific Advisory Board. The company identifies him as Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School.

Mark Stevenson is former COO of Thermo Fisher Scientific and a named personal investor in Relation Therapeutics’ June2022 seed financing.

Matthew Page is VP, Data Science at Relation, contributing computational methods and biological data analysis to its drug-discovery platform.

Michael Bronstein serves on Relation’s Scientific Advisory Board. Relation identifies him as the DeepMind Professor of AI at the University of Oxford; his expertise connects machine learning and drug discovery. Michael Bronstein is CHIEF SCIENTIST IN RESIDENCE at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Peer Schatz is former CEO of Qiagen and a named personal investor in Relation Therapeutics’ June2022 seed financing.

Rosie Rodriguez is President, Growth at Relation, working across the growth of its technology-enabled biopharmaceutical business. The company lists her among its current executive leadership.

Deborah Waterhouse is CEO of ViiV Healthcare and GSK President, Global Health. She became ViiV CEO in April 2017 and joined GSK’s Executive Committee in January 2020. She joined GSK in 1996 and has held senior commercial roles across the US, Europe and Asia Pacific.

Phil Thomson is GSK President, Global Affairs, a role he took in 2017. He leads stakeholder engagement, reputation and policy strategy. He joined Glaxo Wellcome in 1996 and GSK’s Executive Committee in 2011.

Tony Wood became GSK Chief Scientific Officer, Head of R&D and an Executive Committee member in August 2022. He joined GSK from Pfizer in 2017. His work spans medicinal chemistry, genetics, advanced technologies and strategic partnerships, with scientific fellowships including the Royal Society.

Regis Simard is GSK President, Global Supply Chain and joined its Executive Committee in 2018. He leads medicine and vaccine manufacturing and supply, together with corporate quality and environmental health and safety responsibilities. He joined GSK in 2005 after roles at Sony, Konica Minolta and Tyco Healthcare.

David Redfern is GSK President Corporate Development, responsible for corporate development and strategic planning. He joined GSK in 1994 and its Executive Committee in 2008. He has chaired ViiV Healthcare’s board since 2011 and is a chartered accountant.

Shobie Ramakrishnan is GSK Chief Digital and Technology Officer and joined its Executive Committee in 2021. She leads technology and cybersecurity, having joined GSK in 2018. Her earlier technology leadership experience includes AstraZeneca, Salesforce, Genentech and Roche. Insight Partners source, reviewed October 8, 2026: Shobie Ramakrishnan is published in Insight Partners’ official External advisory directory; published employer title: GSK, Chief Digital & Technology Officer directory as GSK, Chief Digital & Technology Officer. The source publishes the name, exact affiliation and portrait but does not supply an expanded career or education biography. External employer responsibilities are source-published context, not an Insight employee or personal-investment claim.

Roanne Parry became GSK Chief People Officer and joined its Executive Committee in May 2026. She leads the company’s people and culture strategy. She previously served as CSL chief human resources officer and had earlier spent 22 years in GSK human resources leadership.

Maya Martinez-Davis is GSK President, US and joined its Executive Committee in 2026. She joined GSK in 2019 following biopharma and oncology leadership roles at Merck KGaA and Pfizer. She is also an independent director of Perspective Therapeutics.

Nina Mojas is GSK President, Global Product Strategy and joined its Executive Committee in 2026. She oversees global commercial strategy, lifecycle management and market access. She joined GSK in 2020 and previously held senior oncology roles at AstraZeneca and an investor-relations role at Roche.

Mondher Mahjoubi is GSK Chief Patient Officer and joined its Executive Committee in 2026. He leads global medical strategy, evidence generation and scientific engagement. He joined GSK in 2024 after serving as Innate Pharma CEO and holding leadership roles at AstraZeneca, Genentech, Roche and Sanofi.

James Ford is GSK Senior Vice President and Group General Counsel, Legal and Compliance. He joined GSK in 1995 and its Executive Committee in 2018, later taking on compliance, security and investigations responsibilities. He previously practiced law at Clifford Chance and DLA.

Mike Crichton is GSK President, International and joined its Executive Committee in 2026. He leads commercial growth outside the US and Europe, including China and Japan. He joined GSK in 2018 following senior roles at Novartis, AstraZeneca and Roche.

Lynn Baxter is GSK President, Europe and joined its Executive Committee in 2026. She leads commercial performance and strategy across European markets. She joined GSK in 2009 and has held senior roles in vaccines and at ViiV Healthcare, following commercial positions at Roche and Merck.

Vishal Sikka is a GSK independent non-executive director appointed in July 2022. He founded Vianai Systems and brings artificial intelligence, machine learning and cybersecurity expertise. He previously served as Infosys CEO and in senior technology and executive-board roles at SAP.

Gavin Screaton is a GSK independent non-executive director appointed in May 2025. His scientific and clinical expertise spans immunology, infectious disease and experimental medicine. He previously served as chair of medicine at Imperial College’s Hammersmith Hospital. Gavin Screaton is named by the University of Oxford as Head of Medical Sciences Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s current Medical Sciences leadership directory independently confirms the headship alongside the separate GSK non-executive directorship; immunology research remains an academic role, not a personal company investment.

Harry Dietz is a GSK independent non-executive director and scientific and medical expert appointed in January 2022. A physician-scientist specializing in human genetics and heritable connective-tissue disorders, he is known for research on Marfan syndrome and disease-modifying approaches in fibrosis and neurodegeneration.

Jeannie Lee is a GSK independent non-executive director and a scientific and medical expert. Her scientific work concerns epigenetics and gene regulation, with expertise in RNA biology and approaches to understanding genetic disease.

Roy Jakobs joined GSK as an independent non-executive director on 13 July 2026. He has served as CEO of Royal Philips since 2022, following international leadership roles at Philips, Shell and Elsevier. He brings experience in healthcare technologies including imaging and patient monitoring.

Wendy Becker is a GSK independent non-executive director appointed in October 2023. Her leadership experience spans technology, consumer businesses and healthcare, including serving as Jack Wills CEO, Vodafone chief marketing officer and a McKinsey partner.

Anne Beal is a physician and entrepreneur serving as a GSK independent non-executive director since May 2021. Her expertise includes patient advocacy, health policy and research access. She previously held leadership roles at the Patient-Centered Outcomes Research Institute and Sanofi and worked at Harvard Medical School and Massachusetts General Hospital.

Hal Barron is a non-executive director of GSK, having transitioned from Chief Scientific Officer and President of R&D in August 2022. He joined its board in 2018 and previously led research and development at Calico. His work emphasizes genetics and technology in drug discovery.

Charles Bancroft is GSK’s Senior Independent Non-Executive Director, having joined its board in May 2020. He retired from Bristol Myers Squibb in 2020 after a career spanning financial, commercial, integration and strategy leadership, including serving as chief financial officer.

Elizabeth McKee Anderson is a GSK independent non-executive director appointed in September 2022. Her commercial biopharmaceutical experience includes leadership in infectious diseases, vaccines, immunology and oncology at Janssen and Wyeth. She has engineering and business qualifications.

Julie Brown became GSK Chief Financial Officer and a board director on 1 May 2023. She previously held senior finance and operating positions at Burberry, Smith & Nephew and AstraZeneca and served on Roche’s board. She is a chartered accountant and tax professional.

Luke Miels became GSK Chief Executive Officer and a board director on 1 January 2026, succeeding Emma Walmsley. He joined GSK as Chief Commercial Officer in 2017 after executive roles at AstraZeneca and Roche. He studied biology at Flinders University and earned an MBA at Macquarie University.

Jonathan Symonds has chaired GSK since September 2019. His background includes chief financial officer positions at Novartis and AstraZeneca, senior roles at Goldman Sachs and KPMG, and board leadership at HSBC. He brings finance, governance and life-sciences experience.

London-headquartered public biopharmaceutical company formed through the Glaxo Wellcome and SmithKline Beecham merger in 2000, with predecessor businesses dating to 1715. GSK develops specialty medicines and vaccines across respiratory, immunology and inflammation, oncology and infectious diseases, including HIV through ViiV Healthcare. It combines human genetics, functional genomics, artificial intelligence and machine learning in drug discovery. Its technology and neuroscience relevance includes strategic research alliances in neurodegeneration and corporate equity investments in discovery platforms such as Relation Therapeutics and human-genetics company 23andMe. Luke Miels became CEO on 1 January 2026; the current board and Executive Committee contain 26 distinct named people. Commercial research payments, licence milestones, acquisitions, share buybacks and ordinary market trading are distinct from equity financing. This profile represents the parent corporation rather than GSK Ventures, Action Potential Venture Capital or independently managed SR One.

Jean-Claude Dardelet serves as Supervisory Board Member — Representative of Cities at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Pascal Feillard serves as Supervisory Board Member — Representative of Industry at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Lenka Scholzova serves as Supervisory Board Member — Representative of Universities at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Zuzana Pickóva serves as Supervisory Board Member — Independent Representative at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Mika Rytkönen serves as Supervisory Board Member — Independent Representative at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Jan Van Den Oetelaar serves as Independent Supervisory Board Chair at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Lina Konstantinopoulou serves as Supervisory Board Member — Independent Representative at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Silvia Simonelli serves as Head of Finance at EIT Urban Mobility. She leads finance planning, budgets, reporting and analysis, including controlling and reporting for EU-funded programmes. She holds a business administration master’s degree from ESADE.

Daniel Moix serves as Head of IT at EIT Urban Mobility. He leads IT applications, infrastructure and services, with experience managing regional technology services. He holds an MBA from Trinity College Dublin and telecommunications and telematics engineering degrees.

Elisa Kerschbaumer serves as Head of PMO at EIT Urban Mobility. She joined the Project Management Office in late 2022 and has led it since early 2026. Her work covers grants management, audits and compliance for European-funded programmes.

Lluis Puerto serves as RIS and EIT Community Director at EIT Urban Mobility. His experience covers safe and sustainable transport, intelligent transport systems, public policy and go-to-market consulting. He formerly served on the boards of ERTICO and EuroRAP.

Willem Frederik Metzelaar serves as Regional Director (West) | Interim Regional Director (North) at EIT Urban Mobility. His background includes commercial leadership in energy utilities, founding data analytics companies, investing and work at EIT Digital.

Judith O'Meara serves as Regional Director at EIT Urban Mobility. She has worked on European research and innovation funding, consortium development and commercialization of research, including at the Max Planck Society and Technical University of Munich.

Martí Massot serves as Regional Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Traian Urban serves as Regional Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Bernadette Bergsma serves as Communications & EU Affairs Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Jaume Campmany serves as Legal Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Philipp Schulte-Noelle is a healthcare executive and angel investor in nyra health. The company and its financing counsel confirm his participation in the 2023 seed; its 2026 Series A announcement names him as a returning investor, corroborated by Austria's official shareholder register.

Sandrine Martin Tran Ba Huy serves as People & Culture Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Adriana Diaz serves as Innovation and Strategy Director at EIT Urban Mobility. Her work covers technology policy and innovation, including autonomous mobility deployment. She holds an engineering and policy analysis MSc and a doctorate in economics of innovation.

Franz Wiesbauer is a healthcare entrepreneur associated with Medmastery and an angel investor. Nyra health's December 2021 issuer announcement names him as a pre-seed participant.

Johannes Braith is an entrepreneur and early-stage investor. Nyra health's December 2021 announcement identifies the Storebox founder as lead investor in its EUR2.2 million pre-seed financing and as a Hardlymountain Capital co-founder.

Lukas Zinnagl is a healthcare entrepreneur and angel investor associated with Diagnosia. Nyra health's December 2021 issuer announcement names him as a participating business angel in its pre-seed financing.

Maria Paula Caycedo serves as Business Development Director at EIT Urban Mobility. Her background spans aeronautics, automotive and consulting, with experience in product development, sales, business expansion and intelligent transport systems.

Martin Vendel serves as Academy Director at EIT Urban Mobility. He combines academic research and teaching with corporate and startup leadership, focusing on strategy, business development and technology-driven industry transformation.

Miguel Ángel Martínez serves as Head of Cabinet at EIT Urban Mobility. His background spans climate science, innovation management and science policy at the University of Southampton, the UK government and the European Commission. He holds environmental sciences degrees from Universitat Autònoma de Barcelona.

Philipp Schöllauf is nyra health's co-founder and chief scientific officer. A neurologist with experience in stroke care and rehabilitation, he leads clinical research and the therapy framework supporting the company's products. He is also a registered managing director.

Sievert Weiss is a healthcare entrepreneur associated with AMBOSS and an angel investor. Nyra health's December 2021 issuer announcement confirms his participation in its pre-seed financing.

Stefan Speiser is a healthcare entrepreneur associated with Latido and an angel investor. Nyra health's December 2021 issuer announcement confirms his participation in its pre-seed financing.

Francisco Ibáñez serves as Chief Financial Officer at EIT Urban Mobility. His background includes consulting at Accenture and McKinsey, strategic planning and management at CEMEX, and business development and fundraising support at EIT Digital. He holds a Harvard MBA and a mechanical engineering degree from the University of Texas at Austin.

Mario Zusag is co-founder and CTO of nyra health. His background includes computer science at TU Vienna, machine learning at Imperial College London and research at Google Brain and IBM Research. He leads the company's multimodal neurorehabilitation technology and is a registered managing director.

Moritz Schöllauf is nyra health's co-founder and CEO. A lawyer with expertise in regulation, data protection and medical-device compliance, he leads strategy, partnerships and regulatory operations. He is also a registered managing director of the company.

European urban mobility innovation community launched in 2019, with headquarters in Barcelona. EIT Urban Mobility links cities, industry, universities and startups to accelerate sustainable transport through investment, innovation projects, education and market deployment. Its governance combines the nonprofit EIT Urban Mobility Association, sole shareholder of the operational EIT KIC Urban Mobility S.L.U. company, with regional innovation hubs and an educational foundation. The initiative is supported by the European Institute of Innovation and Technology, an EU body, and operates an Impact Ventures equity-investment programme alongside separate grants and equity-free accelerators. Its early-stage portfolio includes AI-driven freight operations, rail autonomy, assistive pedestrian navigation and mobility data systems. The current leadership directory names 18 management, regional and corporate leaders and seven supervisory board members. Marc Rozendal has been CEO since April 2025; Denise Xifara leads Impact Ventures. EU programme allocations and planned investment budgets are not completed venture fund closings.

Marc Rozendal serves as Chief Executive Officer at EIT Urban Mobility. He became CEO effective 1 April 2025 after serving as UK managing director at Ola and CEO of Cab Guru. His experience spans transport technology, public transport and business transformation.

HIL-INVENT Ges.m.b.H. is the Hillebrand family office’s Austrian investment vehicle, based in Salzburg and registered in 2009 under FN 333356f. It invests in life sciences, medical technology, pharmaceuticals and related industries, with a stated interest in new neurological treatments. The official Austrian register lists Friedrich Hillebrand and Julia Hillebrand as its managing directors and B.F.H. Privatstiftung as shareholder. Its publicly documented investments include AI neurorehabilitation company nyra health, electronic implant developer UroMems and T-cell therapy developer Captain T Cell. HIL-INVENT is separately registered from the EVER Pharma operating group; nyra’s registered shareholder is HIL-INVENT even where financing publicity uses the EVER Pharma brand. Public fund closings and investment check sizes have not been established. Registered corporate share capital is not a venture fund size. No authentic standalone company logo or own website was verified in public primary sources.

Julia Hillebrand is Managing Director and co-owner of EVER Pharma and a member of its Executive Board. She joined the company in 2013 as Head of Corporate Development and has led its Neurology business unit since 2016. She holds a medical doctorate from the Medical University of Vienna. Nyra health’s CEO publicly acknowledges her support, while its registered equity investor is the separate HIL-INVENT family investment vehicle. The official Austrian register also lists her as a Managing Director of HIL-INVENT Ges.m.b.H., the separately registered Hillebrand family investment vehicle.

Friedrich Hillebrand is Chairman and owner of the EVER Pharma Group. He led EBEWE Pharma as CEO until 2009 and has worked across pharmaceutical development, manufacturing and commercialization for more than four decades. He holds a doctorate in chemical engineering from the University of Vienna. The official Austrian register also lists him as a Managing Director of HIL-INVENT Ges.m.b.H., the separately registered Hillebrand family investment vehicle.

Georges Kahwati is Chief Executive Officer of EVER Neuro Pharma, EVER Valinject and EVER Pharma Jena. Before joining the EVER Pharma Group, he worked at Sandoz International as Global Head of Commercial Operations for oncology injectables and General Manager of its Unterach site. He previously led specialty injectables at EBEWE Pharma and holds a commerce degree from McGill University and an MBA from INSEAD.

EVER Pharma is a privately owned specialty pharmaceutical group headquartered in Unterach, Austria, focused on neurology and complex sterile injectables for oncology, intensive care and hormone therapy. The group traces its origins to EBEWE Pharma, founded in Vienna in 1934; the neurology business was spun off and rebranded EVER Pharma in 2008–2009 when the oncology business was sold to Novartis. Its facilities in Austria and Germany develop and manufacture injectable medicines and drug-delivery devices. Its neurological product portfolio includes Cerebrolysin and Dacepton, alongside D-mine pen and infusion-pump devices for Parkinson’s disease medication delivery; indications and availability depend on the local market. Its published group management includes chairman and owner Friedrich Hillebrand, CEO Georges Kahwati, and managing director and co-owner Julia Hillebrand. The website identifies EVER Neuro Pharma GmbH and EVER Pharma Jena GmbH as operating entities. Although nyra health financing announcements use the EVER Pharma brand, its registered shareholder and historical investment vehicle is the separate Hillebrand family-office entity HIL-INVENT Ges.m.b.H.; those equity participations must not be attributed to the operating pharmaceutical group. Published R&D spending and manufacturing investments are operational expenditure rather than venture financing rounds.

Raj Shah is a director of the NATO Innovation Fund, managing partner of Shield Capital, and co-founder and chair of cyber-insurance company Resilience. He previously led the Pentagon’s Defense Innovation Unit Experimental and Morta Security. He is an F-16 pilot and studied at Princeton and Wharton.

Kusti Salm is a director of the NATO Innovation Fund and CEO of Frankenburg Technologies. He previously served as permanent secretary of Estonia’s defence ministry and led the Estonian Centre for Defence Investment.

Ebru Dorman is a director of the NATO Innovation Fund. Her experience includes HSBC Bank Türkiye, Borusan Ventures, Morgan Stanley Strategic Ventures and Orange Ventures. She earned degrees at Harvard Business School and UC Berkeley. Borusan Ventures publishes Ebru Dorman as an Advisor on its Investment Committee. Its biography describes NATO Innovation Fund and independent corporate board responsibilities, earlier MV Holding and StartersHub leadership, and investment and telecom experience. This committee appointment does not establish a personal cash investment in Borusan portfolio companies.

Prince Constantijn of the Netherlands is a director of the NATO Innovation Fund and co-founder and special envoy of Techleap. His prior roles include European Commission digital-policy leadership and work at RAND.

Roberto Cingolani is a director of the NATO Innovation Fund and CEO and General Manager of Leonardo. He previously served as Italy’s Minister for Ecological Transition and founded the Italian Institute of Technology.

Tarja Jaakkola is a board observer at the NATO Innovation Fund and NATO’s Assistant Secretary General for Defence Industry, Innovation and Armaments. She previously held senior positions in Finland’s defence ministry and the European Defence Agency.

Karl-Christian Agerup is Vice Chair of the NATO Innovation Fund’s board. He is a global partner at Antler and previously co-founded Northzone Ventures and led Oslotech and Hugin.

Fiona Murray chairs the NATO Innovation Fund’s board. She is an MIT Sloan professor and Associate Dean of Innovation, and directs MIT’s Office of Innovation. Her research and advisory work concerns science, technology and innovation policy.

Suzana Ielcean is an Executive Assistant and London Office Manager at the NATO Innovation Fund. Her earlier executive-support experience includes Facebook, Salesforce and Pinterest.

Marrit Leenstra is an Executive Assistant and Amsterdam Office Manager at the NATO Innovation Fund. She previously competed in three Olympic Games in volleyball and beach volleyball.

Mariana Occidente Lupo is an Executive Assistant at the NATO Innovation Fund, supporting its board and senior leadership. She previously assisted the general counsel of Walgreens Boots Alliance and Italy’s defence attaché in London.

Mary De Albergaria is a Platforms and Events Associate at the NATO Innovation Fund.

Veronika Bartakova manages limited-partner and government relationships at the NATO Innovation Fund.

Lennart Velten is an Associate at the NATO Innovation Fund.

David Ordonez is a Senior Associate at the NATO Innovation Fund, working on deep technology investments.

Trisha Saxena is a Senior Associate at the NATO Innovation Fund, researching and supporting deep technology investments.

Joel Noutere is an Adoption Associate at the NATO Innovation Fund.

Lauren Reade leads the NATO Innovation Fund’s adoption platform.

Alex Kugajevsky is an Adoption Principal at the NATO Innovation Fund, supporting the use of portfolio companies’ technologies by customers across the Alliance.

Amalia Kontesi is Chief Communications and Marketing Officer at the NATO Innovation Fund, supporting investment communications and stakeholder relations. Her prior experience includes Google’s EMEA social-impact communications and sustainability communications at JPMorgan Chase.

Susan Wilson is Chief Human Resources Officer at the NATO Innovation Fund. She previously led HR at Mollie and held regional HR leadership roles at Uber, with experience in scaling businesses and organisational change.

Helen Draijer is Chief Financial Officer at the NATO Innovation Fund, overseeing finance and risk. She previously held CFO positions at Avedon Capital Partners and Lagardère Travel Retail Netherlands. She studied accountancy and control at the University of Amsterdam.

John Ridge is Chief Adoption Officer at the NATO Innovation Fund, helping portfolio technologies reach government and industry customers. His prior career spans the British Army and UK government, including operational command and defence intelligence.

Kate O’Brien supports the NATO Innovation Fund’s board and its coordination with senior leadership. A qualified lawyer, she previously served as general counsel and company secretary at Oxford Science Enterprises and advised Lansdowne Partners on private technology investments.

Ari Kristinn Jónsson is President of the NATO Innovation Fund. He previously led Videntifier and a university in Iceland and worked for a decade at NASA. He earned an artificial intelligence doctorate at Stanford in 1997.

Patrick Schneider-Sikorsky is a Partner at the NATO Innovation Fund, leading ecosystem development and Central and Eastern European coverage. He previously co-founded Beast Ventures and invested in AI, autonomy, biotechnology and other deep technologies. He studied at Oxford, the University of London and MIT Sloan.

Sander Verbrugge is a Partner at the NATO Innovation Fund. His experience includes Innovation Industries, NXP Semiconductors and Roland Berger. He holds a TU Delft master’s degree and a molecular biophysics doctorate from Vrije Universiteit Amsterdam.

Erin Hallock is a Partner at the NATO Innovation Fund, working on commercial adoption of deep technologies. She previously served as a managing partner at bp Ventures and held leadership positions at BGF and Barclays.

Ulrich Quay is a Partner at the NATO Innovation Fund. He previously built and led BMW i Ventures, investing across mobility, energy, industrial automation and AI. He holds a doctorate in law from the University of Freiburg.

Independent, multi-sovereign venture capital fund backed by 24 NATO member countries, investing in dual-use deep technology for defence, security and resilience. Launched in 2022, its flagship fund closed on €1 billion in July 2023; current capital exceeds €1 billion after additional sovereign participation. NIF invests directly in startups and through other venture funds, typically entering from seed to Series B with initial investments of up to €15 million and reserves for follow-on financing. Focus areas include AI, autonomy, quantum technologies, biotechnology, advanced materials and manufacturing, space, energy and next-generation communications. Its investment management headquarters are in Amsterdam, with regional offices in London and Warsaw and the fund domiciled in Luxembourg. NIF is commercially independent: capital comes from sovereign limited partners, and NATO itself does not financially invest or make investment decisions. It is separate from the DIANA accelerator. The current official directory lists four investment partners, a president, adoption and operations staff, and eight board members or observers.

Taras Lutsiv is an Investment Associate at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. The current official D3 directory lists this investment team role.

Elya Chiechienieva is a Co-Founder and Partner at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. Denmark’s EIFO identifies this person as one of D3’s three founders in summer 2023.

Anton Verkhovodov is a Co-Founder and Partner at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. Denmark’s EIFO identifies this person as one of D3’s three founders in summer 2023.

Eveline Buchatskiy is a Co-Founder and Managing Partner at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. Denmark’s EIFO identifies this person as one of D3’s three founders in summer 2023.

Sebastian Johnston is a Venture Partner at Armira Growth and a founding partner of La Famiglia. He is an entrepreneur and angel investor and serves as president of Enactus Germany. His personal backing of companies is distinct from institutional Armira Growth investment participation.

Tessa Bottenschein is an Investment Associate at Armira Growth, where her published alumni biography records her joining in 2024 after working at Bain & Company from 2022 to 2024. She studied business administration at St. Gallen and international finance at Nova School of Business and Economics. Her own 2026 investment announcement discusses Armira Growth’s lead investment in AI neurorehabilitation company nyra health.

Christian Figge co-leads Armira’s Growth strategy as Managing Partner. He previously spent more than a decade at General Atlantic, ultimately as Managing Director, and earlier worked at BC Partners and L.E.K. Consulting. He holds a PhD from the Technical University of Munich, an MA in Economics from LMU Munich and a BA in Economics and Management from Oxford.

Florian Tappeiner is a founding partner and Managing Partner of Armira Growth, joining in October 2021. He previously co-led NuCom Group and worked in strategic investments at ProSiebenSat.1, H.I.G. Capital and Allianz. He studied industrial engineering at TU Ilmenau and earned a doctorate in entrepreneurial finance at TU Munich.

Munich-based growth equity investment platform within Armira, founded in 2021 to back European technology and technology-enabled companies. It typically provides EUR10–100 million of growth capital to businesses with proven models, with an emphasis on the DACH region. Its portfolio spans AI, software, industrial technology, aviation automation and digital neurorehabilitation, including TYTAN Technologies, Assaia and nyra health. Armira Growth Fund I reached its EUR200 million final closing in May 2024. The wider Armira platform’s approximately EUR5 billion of managed capital is distinct from this fund’s size. The growth platform is separate from the parent’s Mittelstand buyout and Opportunities strategies.

Batuhan Yumurtacı is CTO and co-founder of TYTAN Technologies and a Technical University of Munich alumnus. He co-founded the company with Balázs Nagy in 2023.

Chris Badia joined TYTAN Technologies' board in 2026. The former German Air Force general served as NATO Deputy Supreme Allied Commander Transformation from July 2022 to July 2025.

Max Enders heads Business Development and Government Affairs at TYTAN Technologies and is the company's named press contact.

Tahsin Kart joined TYTAN Technologies as co-CEO in 2026 to lead industrial scaling. He formerly served as CTO of CycloTech and lead engineer at Roketsan Missiles.

Balázs Nagy is CEO and co-founder of TYTAN Technologies. He studied energy engineering in Budapest and aerospace engineering at the Technical University of Munich, where he founded the HORYZN student drone initiative.

Chloe Legge serves as Marketing Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Nina Litman-Roventa serves as Investment Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Eva Frey serves as Executive Assistant & Office Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Francesco Pomponi serves as Head of Carbon Math at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Jaisal Singh Shergill serves as Fund Operations Analyst at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Paul Eisenberg serves as Investment Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Paola Brenni serves as Investment Associate at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Oliver Schwarzer serves as Partner & CFO at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Fernanda Bartels serves as Marketing Director at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Christian Guba serves as Principal at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Moritz Kötter serves as Investment Associate at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Joern-Carlos Kuntze serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Tess Dury serves as Director of Impact & ESG at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Sebastian Heitmann serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Torben Schreiter serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Carlota Ochoa Neven Du Mont serves as Principal at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

D3 (Dare to Defend Democracy) is an early-stage venture investor founded in 2023 by Eveline Buchatskiy, Anton Verkhovodov and Elya Chiechienieva. Operating from Ukraine and bridging its startup ecosystem with NATO allies, it backs deep technologies for national security, including artificial intelligence, autonomous systems, drones, electronic warfare, sensors, mission systems and demining. D3 currently advertises initial investments of $500,000–$1.5 million at pre-seed and seed, using equity or convertible instruments and offering follow-on capital and operational support. Its published portfolio includes TYTAN Technologies, Swarmer, Buntar Aerospace, Ailand Systems, Cambridge Aerospace, Agon and Neros. Denmark’s EIFO joined as a fund investor in July 2025. D3 Fund, LP is separately identified in EIFO’s public disclosures; an individual LP investment and reported fundraising targets do not establish the fund’s final closing size. The current published team has four members.

Berlin-based venture capital firm backing early-stage climate technology companies, primarily in Europe. Extantia invests in hardware and software for energy, industrial processes, buildings, transportation and carbon removal, generally at Seed to Series A with initial investments of €1–5 million. Its deep-technology portfolio includes robotics, trapped-ion quantum computing, green hydrogen, synthetic fuels and industrial materials. The firm operates direct-investment Flagship funds and the Allstars climate venture fund-of-funds strategy, alongside its earlier Pledge proof-of-concept fund. Extantia Climate Flagship II completed its final close at €204 million in 2024; the approximately €300 million platform/AUM figure describes combined strategies rather than another single closed fund. Extantia’s current directory lists 17 team members across Germany and the UK.

Yair Reem serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Andreas Lächelt is Head of Group Accounting at NexDash. Entrepreneur and experienced accounting leader. Leads group accounting, consolidation and financial reporting at NexDash.

Beacon Partners adviser. Beacon’s published advisory directory describes Andrew Nodes as VP Supply Chain, Instacart. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Anil Varanasi as Founder & CEO, Meter. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Arnaud Ferreri as CTO, Headway. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Bob Hardester as Former CIO, Schnucks Markets. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Charlie Fang as Product, Surge AI; prev. Hertz. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Dani Dudeck as CCO, Netflix. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Doug Rogers as VP, Lumeris. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Euan Blair as Founder & CEO, Multiverse. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Farhan Thawar as VP & Head of Eng, Shopify. This is an external advisory relationship with Beacon.

CTO of Beacon, appointed in June 2026. Previously AngelList CTO and a senior engineering leader at Coinbase.

Beacon Partners adviser. Beacon’s published advisory directory describes Jake Bornstein as Co-Founder, Studio Metis. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes James Dyett as Former Head of Enterprise Sales, OpenAI. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Karney Li as Former Chief Architect, Wealthsimple. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Laura Chmar as Former VP Medicare, Aledade. This is an external advisory relationship with Beacon.

Vice President of AI Research at Beacon following its September 2026 acquisition of Haize Labs. Leads initiatives to deploy reliable AI across Beacon’s software businesses.

COO and CPO of Beacon, appointed in June 2026 to scale its AI operating platform. Previously CTO of Instacart and Superhuman.

Beacon Partners adviser. Beacon’s published advisory directory describes Mary Miller as Founder, Ciconia; prev. Amazon. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Max Schnoedl as Chair, GovPilot; prev. COO Accela. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Michael Tully as Founder & CEO, Journey Holdings. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Morgan Fong as General Counsel, Instacart. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Nikhil Shanbang as VP Competition Law, Meta. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Nikila Srinivasan as Former VP Product Management, Meta. This is an external advisory relationship with Beacon.

Founder and CEO of Beacon, a permanent holding company that acquires essential software businesses and modernizes them with AI and shared operating resources. Former President of Instacart and partner at D1 Capital.

Beacon Partners adviser. Beacon’s published advisory directory describes Rob Crisci as Former CFO Lineage Logistics. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Ryan Pinder as Former Attorney General, Bahamas. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Sagar Sanghavi as Former CFO Abridge. This is an external advisory relationship with Beacon.

Co-founder and CTO of Metaview, the AI recruiting platform he co-founded in 2018 with Siadhal Magos.

Co-founder and CEO of Metaview, the AI recruiting platform he co-founded in 2018 after building teams at Uber and Palantir with Shahriar Tajbakhsh.

Beacon Partners adviser. Beacon’s published advisory directory describes Suzanne Behrens as Former CMO, Granicus. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Suze Skop as Sr. Director, Agencies, Instacart. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Will Petrie as CFO, Ramp. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Will Simmons as Product, Ramp. This is an external advisory relationship with Beacon.

Blue J develops an AI tax research platform for accountants, tax advisers and other tax professionals. Its generative AI system answers tax questions and supports research, analysis and drafting with citations to primary authorities and specialist content including Tax Notes and IBFD. It is designed to help professionals evaluate relevant sources and apply their own judgment to complex tax issues. Founded in Toronto in 2015, Blue J serves tax firms in the United States, Canada and United Kingdom; its generative tax research product launched in 2023.

Iterative Health is a healthcare technology and services company that uses AI, clinical-trial expertise and centralized operations to run a research-site network embedded in community medical care. It helps pharmaceutical sponsors, CROs and investigators select and activate trial sites, recruit patients and conduct studies in gastroenterology, hepatology, obesity and cardiology. Founded in 2017, it is based in Cambridge, Massachusetts, and New York.

StackAdapt builds an AI advertising and marketing platform for brands and agencies. Its demand-side platform lets marketers plan, buy, target, optimize and measure campaigns across connected TV, display, native, video, audio, digital out-of-home and in-game advertising. The platform also connects paid advertising with owned channels such as email and direct mail, first-party data and creative workflows; its Ivy Studio AI workspace helps with campaign analysis, planning and execution. Founded in Toronto in 2014, StackAdapt serves customers internationally.

Law professor and Blue J legal innovation strategist; formerly its Vice President of Legal Research.

Adam Keating is a mechanical engineer turned founder who started CoLab after realizing how much innovation is lost when engineers spend more time managing files and feedback than solving problems. At ExxonMobil and RefleXion Medical, he saw firsthand how these inefficiencies slow down even the most advanced teams. Adam co-founded CoLab to help organizations make better design decisions, faster—accelerating how complex products come to life.

Blue J co-founder and University of Toronto law and economics scholar.

Leads StackAdapt client services; promoted from SVP, Global Client Services in October 2026.

Blue J co-founder and University of Toronto law professor researching artificial intelligence, law and economics.

Tax law scholar and entrepreneur who co-founded Blue J in 2015; holds the Osler Chair in Business Law at the University of Toronto.

Leads StackAdapt’s global finance and accounting functions; previously CFO at Kinaxis and a finance executive at Shopify.

Technology executive and co-founder of Blue J with software architecture and delivery experience.

Sapphire Ventures partner who joined Blue J’s board with its August 2025 Series D financing.

Professor of public health and clinical epidemiology at Exeter, researching diagnostic test evaluation.

Chief Revenue Officer at StackAdapt.

Practicing GP working in AI and digital health.

Chartered accountant with finance and operations experience in startups and regulated lending.

Healthcare chair and adviser; previously chaired UCLPartners and two NHS trusts.

Gabriel Grunberg is Head of Business Intelligence & Analytics at NexDash. Former VP Planning & Analysis at Grover. Leads business intelligence and performance analytics at NexDash.

Leads financial strategy at Blue J; previously CFO at Miovision with experience at PointClickCare and Ataccama.

Leads inventory development at StackAdapt.